Pharma
Spanish stocks - Factors to watch on Jan 24
- January 24, 2023 08:55 AM CET | Reuters

287 Jan 24 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:
Pharma Mar's Licensing Partner Receives Full Approval For Commercialisation For Zepzelca In Mexico
- January 24, 2023 08:42 AM CET
- Reuters
CORRECTED-(OFFICIAL)-Spanish stocks - Factors to watch on Jan 18
- January 18, 2023 09:51 AM CET
- Reuters
Oryzon Says First Patient Enrolled In Phase II Collaborative Study With Iadademstat
- January 18, 2023 08:30 AM CET
- Reuters

Oryzon Genomics Informs On Conversion Of Convertible Bonds
- January 17, 2023 08:46 AM CET | Reuters
Jan 17 (Reuters) - Oryzon Genomics SA: * ANNOUNCES CONVERSION OF CONVERTIBLE BONDS * INVESTOR NICE & GREEN HAS REQUESTED A NEW CONVERSION OF BONDS FOR AN AMOUNT JOINT FACE VALUE OF 1.9 MILLION EUROS,
Read More...
Grifols Achieves Positive Topline Results From Phase 3B Study Of Fibrin Sealant
- January 11, 2023 02:07 PM CET | Reuters
Jan 11 (Reuters) - Grifols SA: * ACHIEVES POSITIVE TOPLINE RESULTS FROM PHASE 3B STUDY OF ITS FIBRIN SEALANT TO TREAT SURGICAL BLEEDING IN PEDIATRIC PATIENTS * ALL PRIMARY AND SECONDARY ENDPOINTS MET,
Read More...
Pharma Mar Initiates First Human Clinical Trial Of New Molecule For Cancer Patients
- December 30, 2022 08:33 AM CET | Reuters
Dec 30 (Reuters) - Pharma Mar SA: * INITIATES FIRST HUMAN CLINICAL TRIAL OF A NEW MOLECULE, PM534, FOR CANCER PATIENTS * NEW MOLECULE HAS BEEN TESTED IN THE LABORATORY, BOTH IN CELL CULTURES (IN VITRO
Read More...
Pharma Mar Leads Research Project In Search Of Immunotherapies Based On Marine-Derived Compounds
- December 22, 2022 08:54 AM CET | Reuters
Dec 22 (Reuters) - Pharma Mar SA: * LEADS TERINMUN INITIATIVE, RESEARCH CONSORTIUM IN SEARCH OF IMMUNOTHERAPIES BASED ON MARINE-DERIVED COMPOUNDS * PROJECT APPROVED IN CALL FOR PUBLIC-PRIVATE
Read More...
Oryzon Genomics: Investor Nice & Green Converts Bonds For Nominal Amount Of 1.8 Mln Euros
- December 20, 2022 04:50 PM CET | Reuters
Dec 20 (Reuters) - Oryzon Genomics SA: * CONVERSION OF CONVERTIBLE BONDS * INVESTOR HAS PROCEEDED TO CONVERT BONDS FOR A NOMINAL AMOUNT SET OF 1.8 MILLION EUROS, AT A CONVERSION PRICE OF 2.1995 EUROS
Read More...
Oryzon Genomics Gets EU Grant To Explore Iadademstat Role In Oncological Immunotherapy Approaches
- December 16, 2022 08:00 AM CET | Reuters
Dec 16 (Reuters) - Oryzon Genomics SA: * GETS EU GRANT TO FURTHER EXPLORE ROLE OF IADADEMSTAT IN ONCOLOGICAL IMMUNOTHERAPY APPROACHES * PROJECT WILL START ON MAY 1, 2023 AND WILL RUN FOR TWO YEARS *
Read More...
Grifols considers selling 2 bln euros worth of assets to cut debt, Cinco Dias says
- December 14, 2022 10:00 AM CET | Reuters
MADRID, Dec 14 (Reuters) - Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing
Read More...
Spanish stocks - Factors to watch on Dec 14
- December 14, 2022 08:35 AM CET | Reuters
Dec 14 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy
Read More...
Laboratorio Reig Jofre Completes Co-Development Of Trifertyatm
- December 13, 2022 11:49 AM CET | Reuters
Dec 13 (Reuters) - Laboratorio Reig Jofre SA: * HAS SUCCESSFULLY COMPLETED CO-DEVELOPMENT OF TRIFERTYATM, FOOD SUPPLEMENT THAT CONTRIBUTES TO MALE FERTILITY Further company coverage: (Gdansk Newsroom)
Read More...
Spanish stocks - Factors to watch on Dec 13
- December 13, 2022 08:53 AM CET | Reuters
Dec 13 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:
Read More...Frequently Asked Questions
Testing
3232